Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib dose-escalation with radiotherapy for laryngeal and oropharyngeal squamous cell carcinoma
NL-OMON43772Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of olaparib in laryngeal squamous cell carcinoma (LSCC), oropharyngeal squamous cell carcinoma (OPSCC) and head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence of dose-limiting toxicities. Started Sep 2014; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
laryngeal squamous cell carcinoma (LSCC)oropharyngeal squamous cell carcinoma (OPSCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON43772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43772.